141 related articles for article (PubMed ID: 37580515)
1. Mycophenolate mofetil reduces the risk of relapse in anti-leucine-rich glioma-inactivated protein 1 encephalitis: a prospective observational cohort study.
Liu M; Xu X; Fan S; Ren H; Zhao Y; Guan H
Neurol Sci; 2024 Jan; 45(1):253-260. PubMed ID: 37580515
[TBL] [Abstract][Full Text] [Related]
2. Mycophenolate mofetil, azathioprine and methotrexate usage in paediatric anti-NMDAR encephalitis: A systematic literature review.
Nosadini M; Mohammad SS; Toldo I; Sartori S; Dale RC
Eur J Paediatr Neurol; 2019 Jan; 23(1):7-18. PubMed ID: 30318435
[TBL] [Abstract][Full Text] [Related]
3. CHI3L1 in the CSF is a potential biomarker for anti-leucine-rich glioma inactivated 1 encephalitis.
Li J; Li H; Wang Y; Zhao X; Wang S; Li L
Front Immunol; 2022; 13():1071219. PubMed ID: 36685530
[TBL] [Abstract][Full Text] [Related]
4. Neurological, psychiatric, and sleep investigations after treatment of anti-leucine-rich glioma-inactivated protein 1 (LGI1) encephalitis in Spain: a prospective cohort study.
Muñoz-Lopetegi A; Guasp M; Prades L; Martínez-Hernández E; Rosa-Justícia M; Patricio V; Armangué T; Rami L; Borràs R; Castro-Fornieles J; Compte A; Gaig C; Santamaria J; Dalmau J;
Lancet Neurol; 2024 Mar; 23(3):256-266. PubMed ID: 38365378
[TBL] [Abstract][Full Text] [Related]
5. [Clinical features and outcomes in relapsing and monophasic patients with anti-leucine-rich glioma-inactivated 1 encephalitis].
Li JM; Ma XR; Peng T; Li JH; Lu H
Zhonghua Yi Xue Za Zhi; 2020 Jul; 100(25):1947-1951. PubMed ID: 32629594
[No Abstract] [Full Text] [Related]
6. Clinical characteristics, long-term functional outcomes and relapse of anti-LGI1/Caspr2 encephalitis: a prospective cohort study in Western China.
Guo K; Liu X; Lin J; Gong X; Li A; Liu Y; Zhou D; Hong Z
Ther Adv Neurol Disord; 2022; 15():17562864211073203. PubMed ID: 35069805
[TBL] [Abstract][Full Text] [Related]
7. Clinical features and outcomes of leucine-rich glioma-inactivated protein 1 and contactin protein-like 2 antibody-associated autoimmune encephalitis in a Chinese cohort.
Li HY; Qiao S; Cui CS; Feng F; Liu XW; Yang XD
J Clin Neurosci; 2022 Jul; 101():137-143. PubMed ID: 35597061
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein antibody-associated disorders: A prospective study.
Li S; Ren H; Xu Y; Xu T; Zhang Y; Yin H; Zhang W; Li J; Ren X; Fang F; Li W; Zhu Y; Peng B; Wang J; Zhong Y; Cui L
Neurol Neuroimmunol Neuroinflamm; 2020 May; 7(3):. PubMed ID: 32170045
[TBL] [Abstract][Full Text] [Related]
9. Clinical Features and Long-Term Outcomes of Anti-Leucine-Rich Glioma-Inactivated 1 Encephalitis: A Multi-Center Study.
Qiao S; Wu HK; Liu LL; Wang ML; Zhang RR; Han T; Liu XW
Neuropsychiatr Dis Treat; 2021; 17():203-212. PubMed ID: 33531809
[TBL] [Abstract][Full Text] [Related]
10. Clinical features of anti-leucine-rich glioma-inactivated 1 encephalitis in northeast China.
Zhao Q; Sun L; Zhao D; Chen Y; Li M; Lu Y; Li G; Lin W
Clin Neurol Neurosurg; 2021 Apr; 203():106542. PubMed ID: 33706063
[TBL] [Abstract][Full Text] [Related]
11. Clinical Features, Immunotherapy, and Outcomes of Anti-Leucine-Rich Glioma-Inactivated-1 Encephalitis.
Huang X; Fan C; Gao L; Li L; Ye J; Shen H
J Neuropsychiatry Clin Neurosci; 2022; 34(2):141-148. PubMed ID: 34794327
[TBL] [Abstract][Full Text] [Related]
12. Mycophenolate mofetil in paediatric autoimmune or immune-mediated diseases of the central nervous system: clinical experience and recommendations.
Nosadini M; Gadian J; Lim M; Sartori S; Thomas T; Dale RC
Dev Med Child Neurol; 2019 Apr; 61(4):458-468. PubMed ID: 30221751
[TBL] [Abstract][Full Text] [Related]
13. Rituximab Treatment and Long-term Outcome of Patients With Autoimmune Encephalitis: Real-world Evidence From the GENERATE Registry.
Thaler FS; Zimmermann L; Kammermeier S; Strippel C; Ringelstein M; Kraft A; Sühs KW; Wickel J; Geis C; Markewitz R; Urbanek C; Sommer C; Doppler K; Penner L; Lewerenz J; Rößling R; Finke C; Prüss H; Melzer N; Wandinger KP; Leypoldt F; Kümpfel T;
Neurol Neuroimmunol Neuroinflamm; 2021 Nov; 8(6):. PubMed ID: 34599001
[TBL] [Abstract][Full Text] [Related]
14. The Efficacy and Tolerability of Mycophenolate Mofetil in Treating Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder in Western China.
Chen H; Zhang Y; Shi Z; Feng H; Yao S; Xie J; Zhou H
Clin Neuropharmacol; 2016; 39(2):81-7. PubMed ID: 26818042
[TBL] [Abstract][Full Text] [Related]
15. Dose effects of mycophenolate mofetil in Chinese patients with neuromyelitis optica spectrum disorders: a case series study.
Jiao Y; Cui L; Zhang W; Zhang C; Zhang Y; Zhang X; Jiao J
BMC Neurol; 2018 Apr; 18(1):47. PubMed ID: 29688841
[TBL] [Abstract][Full Text] [Related]
16. Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder.
Huh SY; Kim SH; Hyun JW; Joung AR; Park MS; Kim BJ; Kim HJ
JAMA Neurol; 2014 Nov; 71(11):1372-8. PubMed ID: 25199960
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
Ma J; Yu H; Wang H; Zhang X; Feng K
J Neuroimmunol; 2022 Feb; 363():577790. PubMed ID: 34959021
[TBL] [Abstract][Full Text] [Related]
18. Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder.
Chen H; Qiu W; Zhang Q; Wang J; Shi Z; Liu J; Lian Z; Feng H; Miao X; Zhou H
Eur J Neurol; 2017 Jan; 24(1):219-226. PubMed ID: 27783452
[TBL] [Abstract][Full Text] [Related]
19. Neurofunctional outcomes in patients with anti-leucine-rich glioma inactivated 1 encephalitis.
Chen W; Wang M; Gao L; Huang Z; Lin Y; Xue Q; Liu G; Zhang Y; Su Y
Acta Neurol Scand; 2021 Dec; 144(6):632-639. PubMed ID: 34314015
[TBL] [Abstract][Full Text] [Related]
20. Predictors and Clinical Characteristics of Relapses in LGI1-Antibody Encephalitis.
Campetella L; Farina A; Villagrán-García M; Villard M; Benaiteau M; Timestit N; Vogrig A; Picard G; Rogemond V; Psimaras D; Rafiq M; Chanson E; Marchal C; Goncalves D; Joubert B; Honnorat J; Muñiz-Castrillo S
Neurol Neuroimmunol Neuroinflamm; 2024 May; 11(3):e200228. PubMed ID: 38603771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
